Unveiling protection: a meta-analysis of tixagevimab-cilgavimab prophylaxis in 28,950 transplant recipients and immunocompromised patients against COVID-19
Abstract Background This meta-analysis addresses the efficacy and safety of tixagevimab-cilgavimab as pre-exposure prophylaxis against COVID-19 in immunocompromised patients, particularly during the Omicron variant surge. Given the limited vaccine response in this population, alternative prophylacti...
Saved in:
| Main Authors: | Mostafa Hossam El Din Moawad, Abdallah Abbas, Haneen Sabet, Mohamed Ahmed Zanaty, Abdullah Ashraf Hamad, Ayoub Rezkallah, Osama Ballut, Taha Fayad, Mona Mahmoud Elsakka, Francis Eshun, Hussien Ahmed H. Abdelgawad |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-06-01
|
| Series: | Virology Journal |
| Online Access: | https://doi.org/10.1186/s12985-025-02814-7 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Dose-dependent impact of tixagevimab–cilgavimab as primary prevention against SARS-CoV-2 in immunocompromised individuals
by: Daniela Dluzynski, et al.
Published: (2025-05-01) -
Pharmacoeconomic analysis of tixagevimab and cilgavimab combination for COVID-19 therapy
by: M. V. Zhuravleva, et al.
Published: (2023-07-01) -
Immunogenicity and safety of tixagevimab-cilgavimab for COVID-19 pre-exposure prophylaxis in immunocompromised 20 to <40 kg children and adolescents: A pilot, prospective, open-labeled study
by: Jassada Buaboonnam, et al.
Published: (2024-12-01) -
Experience with Tixagevimab and Cilgavimab (Evusheld) in 86 rheumatic patients undergoing anti-B cell therapy with rituximab
by: T. V. Beketova, et al.
Published: (2023-04-01) -
Tixagevimab/cilgavimab or placebo for COVID-19 in ACTIV-2: Safety, pharmacokinetics and neutralizing and anti-drug antibodies
by: Rachel A. Bender Ignacio, et al.
Published: (2025-03-01)